Novel statistical approach for evaluating flow cytometric in vitro micronucleus data

Autor: J P, Wojciechowski, C R, Gleason, D J, Roberts, L L, Custer

Publikováno v: Environmental and molecular mutagenesis. 57(8)

Statistical methods currently recommended for analysis of in vitro micronucleus data are based on small sample sizes. The tests are designed to evaluate linear trends and differences between treated and control samples. When using flow cytometric ana

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::cff3fbbc82b02ee24dce1e2825079b29
https://pubmed.ncbi.nlm.nih.gov/27545269

The role of genetic toxicology in drug discovery and optimization

Autor: K S Sweder, L L Custer

Publikováno v: Current drug metabolism. 9(9)

Genetic toxicology data is used as a surrogate for long-term carcinogenicity data during early drug development. The aim of genotoxicity testing is to identify potentially hazardous drug candidates. Results from genetic toxicology tests in combinatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85f952bf7edc4d40617abecb5ca492ae
https://pubmed.ncbi.nlm.nih.gov/18991595

Gait kinematics and kinetics in patients with chronic ankle instability and healthy controls: A statistical parametric mapping analysis.

Autor: Herb CC; Northern Kentucky University, School of Kinesiology, Counseling and Rehabilitative Science, Highland Heights, KY, USA. Electronic address: Herbc1@nku.edu., Custer L; Towson University, Department of Kinesiology, Towson, MD, USA., Blemker S; University of Virginia, School of Engineering and Applied Science, Charlottesville, VA, USA., Saliba S; University of Virginia, Curry School of Education and Human Development, Charlottesville, VA, USA., Hart J; University of Virginia, Curry School of Education and Human Development, Charlottesville, VA, USA., Hertel J; University of Virginia, Curry School of Education and Human Development, Charlottesville, VA, USA.

Publikováno v: Foot (Edinburgh, Scotland) [Foot (Edinb)] 2024 Jun; Vol. 59, pp. 102089. Date of Electronic Publication: 2024 Mar 24.

Potential impurities in drug substances: Compound-specific toxicology limits for 20 synthetic reagents and by-products, and a class-specific toxicology limit for alkyl bromides.

Autor: Bercu JP; Gilead Sciences, 333 Lakeside Drive, Foster City, CA, USA. Electronic address: jbercu@gilead.com., Galloway SM; MRL, Merck & Co., Inc., W 45-316, West Point, PA, USA., Parris P; AstraZeneca, Drug Safety and Metabolism, Innovative Medicines and Early Development, United Kingdom., Teasdale A; AstraZeneca, Silk Road Business Park, Macclesfield, Cheshire, SK10 2NX, United Kingdom., Masuda-Herrera M; Gilead Sciences, 333 Lakeside Drive, Foster City, CA, USA., Dobo K; Pfizer Worldwide Research and Development, Genetic Toxicology, Eastern Point Road, Groton, CT, USA., Heard P; Pfizer Worldwide Research and Development, Genetic Toxicology, Eastern Point Road, Groton, CT, USA., Kenyon M; Pfizer Worldwide Research and Development, Genetic Toxicology, Eastern Point Road, Groton, CT, USA., Nicolette J; AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL, USA., Vock E; Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str., 88397 Biberach, Germany., Ku W; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA., Harvey J; GlaxoSmithKline R&D, Park Road, Ware, Hertfordshire, SG12 0DP, United Kingdom., White A; GlaxoSmithKline R&D, Park Road, Ware, Hertfordshire, SG12 0DP, United Kingdom., Glowienke S; Novartis AG, NIBR, Klybeckstrasse, CH-4057 Basel, Switzerland., Martin EA; AstraZeneca, Drug Safety and Metabolism, Innovative Medicines and Early Development, United Kingdom., Custer L; Bristol-Myers Squibb, 1 Squibb Dr, New Brunswick, NJ, USA., Jolly RA; Eli Lilly and Company, Indianapolis, IN, USA., Thybaud V; Sanofi, Vitry-sur-Seine, France.

Publikováno v: Regulatory toxicology and pharmacology : RTP [Regul Toxicol Pharmacol] 2018 Apr; Vol. 94, pp. 172-182. Date of Electronic Publication: 2018 Feb 09.

Bacterial mutagenicity screening in the pharmaceutical industry.

Autor: Escobar PA; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT 06877-0368, USA. Electronic address: patricia.escobar@boehringer-ingelheim.com., Kemper RA; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT 06877-0368, USA., Tarca J; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT 06877-0368, USA., Nicolette J; AbbVie, Abbott Park, IL 60064-3500, USA., Kenyon M; Pfizer Global Research and Development, Groton, CT, USA., Glowienke S; Novartis Pharma AG, Werk Klybeck Klybeckstrasse 141, Basel, CH-4057, Switzerland., Sawant SG; Amgen Inc., Thousand Oaks, CA 91320-1799, USA., Christensen J; Merck Research Laboratories West Point, PA 19486, USA., Johnson TE; Merck Research Laboratories West Point, PA 19486, USA., McKnight C; Merck Research Laboratories West Point, PA 19486, USA., Ward G; Merck Research Laboratories West Point, PA 19486, USA., Galloway SM; Merck Research Laboratories West Point, PA 19486, USA., Custer L; Bristol Myers-Squib, New Brunswick, NJ 08903, USA., Gocke E; Hoffman-La Roche Ltd, Basle, Switzerland., O'Donovan MR; AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK., Braun K; Sanofi-Aventis Deutschland GmbH, D-65926 Frankfurt, Germany., Snyder RD; Merck Research Laboratories West Point, PA 19486, USA; RDS consulting services, Maineville, Ohio. 45039, USA., Mahadevan B; Merck Research Laboratories West Point, PA 19486, USA.

Publikováno v: Mutation research [Mutat Res] 2013 Apr-Jun; Vol. 752 (2), pp. 99-118. Date of Electronic Publication: 2012 Dec 20.